RSS-Feed abonnieren
PDF herunterladen
DOI: 10.1055/s-0040-1717136
Importance of Immediate Thiamine Therapy in Children with Suspected Thiamine-Responsive Megaloblastic Anemia—Report on Two Patients Carrying a Novel SLC19A2 Gene Mutation
Abstract
Thiamine-responsive megaloblastic anemia (TRMA) is an autosomal recessive disorder characterized by the development of megaloblastic anemia, diabetes mellitus, and sensorineural deafness. We report on the first two Croatian patients with TRMA, compound heterozygotes for nonsense, c.373C > T; p.(Gln125Ter) and novel missense variant, c.1214C > G; p.(Thr405Arg) in SLC19A2 gene. The first was diagnosed at 4 months with diabetes mellitus and severe anemia requiring transfusions. As TRMA was suspected, thiamine therapy was immediately started to prevent further transfusions and insulin therapy. His brother developed extreme anemia at 3 weeks of age while waiting for the results of the genetic test. Severe anemia in this sibling may have been prevented if thiamine had been initiated earlier.
Publikationsverlauf
Eingereicht: 27. Juni 2020
Angenommen: 26. August 2020
Artikel online veröffentlicht:
08. Oktober 2020
© 2020. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Porter FS, Rogers LE, Sidbury Jr JB. Thiamine-responsive megaloblastic anemia. J Pediatr 1969; 74 (04) 494-504
- 2 Shaw-Smith C, Flanagan SE, Patch AM. et al. Recessive SLC19A2 mutations are a cause of neonatal diabetes mellitus in thiamine-responsive megaloblastic anaemia. Pediatr Diabetes 2012; 13 (04) 314-321
- 3 Bergmann AK, Sahai I, Falcone JF. et al. Thiamine-responsive megaloblastic anemia: identification of novel compound heterozygotes and mutation update. J Pediatr 2009; 155 (06) 888-892.e1
- 4 Liberman MC, Tartaglini E, Fleming JC, Neufeld EJ. Deletion of SLC19A2, the high affinity thiamine transporter, causes selective inner hair cell loss and an auditory neuropathy phenotype. J Assoc Res Otolaryngol 2006; 7 (03) 211-217
- 5 Habeb AM, Flanagan SE, Zulali MA. International Neonatal Diabetes Consortium. et al. Pharmacogenomics in diabetes: outcomes of thiamine therapy in TRMA syndrome. Diabetologia 2018; 61 (05) 1027-1036
- 6 Kipioti A, George ND, Hoffbrand AV, Sheridan E. Cone-rod dystrophy in thiamine-responsive megaloblastic anemia. J Pediatr Ophthalmol Strabismus 2003; 40 (02) 105-107
- 7 Meire FM, Van Genderen MM, Lemmens K, Ens-Dokkum MH. Thiamine-responsive megaloblastic anemia syndrome (TRMA) with cone-rod dystrophy. Ophthalmic Genet 2000; 21 (04) 243-250
- 8 Ricketts CJ, Minton JA, Samuel J. et al. Thiamine-responsive megaloblastic anaemia syndrome: long-term follow-up and mutation analysis of seven families. Acta Paediatr 2006; 95 (01) 99-104
- 9 Potter K, Wu J, Lauzon J, Ho J. Beta cell function and clinical course in three siblings with thiamine-responsive megaloblastic anemia (TRMA) treated with thiamine supplementation. J Pediatr Endocrinol Metab 2017; 30 (02) 241-246
- 10 Onal H, Bariş S, Ozdil M. et al. Thiamine-responsive megaloblastic anemia: early diagnosis may be effective in preventing deafness. Turk J Pediatr 2009; 51 (03) 301-304
- 11 Mikstiene V, Songailiene J, Byckova J. et al. Thiamine responsive megaloblastic anemia syndrome: a novel homozygous SLC19A2 gene mutation identified. Am J Med Genet A 2015; 167 (07) 1605-1609
- 12 European Commission, Health & Consumer Protection Directorate-General. Opinion of the Scientific Committee on Food on the Tolerable Upper Intake Level of Vitamin B1 Official report. 2001 , Accessed August 6, 2020 at: https://ec.europa.eu/food/sites/food/files/safety/docs/sci-com_scf_out93_en.pdf